Compare PRGO & SSSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRGO | SSSS |
|---|---|---|
| Founded | 1887 | 2010 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 223.3M |
| IPO Year | 1991 | N/A |
| Metric | PRGO | SSSS |
|---|---|---|
| Price | $13.27 | $9.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $22.00 | $10.13 |
| AVG Volume (30 Days) | ★ 4.8M | 156.0K |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | 8.77% | ★ 10.56% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.61 |
| Revenue | ★ $4,281,800,000.00 | $2,354,933.00 |
| Revenue This Year | N/A | $7,183.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.63 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.17 | $4.21 |
| 52 Week High | $30.93 | $10.34 |
| Indicator | PRGO | SSSS |
|---|---|---|
| Relative Strength Index (RSI) | 38.12 | 53.81 |
| Support Level | $12.74 | $8.97 |
| Resistance Level | $13.63 | $9.60 |
| Average True Range (ATR) | 0.43 | 0.29 |
| MACD | 0.24 | -0.01 |
| Stochastic Oscillator | 38.27 | 72.70 |
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.